Short Interest in Dyadic International, Inc. (NASDAQ:DYAI) Declines By 19.9%

Dyadic International, Inc. (NASDAQ:DYAI) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 96,600 shares, a decline of 19.9% from the February 13th total of 120,600 shares. Based on an average daily trading volume, of 90,700 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.5% of the shares of the company are sold short.

Dyadic International Stock Performance

Shares of DYAI traded down $0.02 during mid-day trading on Tuesday, reaching $1.38. The company’s stock had a trading volume of 296,590 shares, compared to its average volume of 68,522. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.54. Dyadic International has a 1-year low of $0.93 and a 1-year high of $2.67. The business has a 50-day simple moving average of $1.51 and a two-hundred day simple moving average of $1.42. The stock has a market cap of $40.83 million, a P/E ratio of -6.00 and a beta of 0.95.

Institutional Investors Weigh In On Dyadic International

Several hedge funds have recently added to or reduced their stakes in the business. Inlet Private Wealth LLC bought a new position in shares of Dyadic International in the fourth quarter valued at about $52,000. Truist Financial Corp acquired a new position in Dyadic International in the 4th quarter valued at about $428,000. Two Sigma Securities LLC bought a new position in Dyadic International in the 4th quarter valued at about $25,000. Jane Street Group LLC acquired a new stake in Dyadic International during the fourth quarter worth approximately $45,000. Finally, Bank of America Corp DE boosted its holdings in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares during the period. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.